2021
DOI: 10.1128/jcm.01731-20
|View full text |Cite
|
Sign up to set email alerts
|

Highly Sensitive and Specific Multiplex Antibody Assays To Quantify Immunoglobulins M, A, and G against SARS-CoV-2 Antigens

Abstract: Reliable serological tests are required to determine the prevalence of antibodies against SARS-CoV-2 and to characterise immunity to the disease in order to address key knowledge gaps in the COVID-19 pandemic. Quantitative suspension array technology (qSAT) assays based on the xMAP Luminex platform overcome the limitations of rapid diagnostic tests and ELISA with their higher precision, dynamic range, throughput, miniaturization, cost-efficacy and multiplexing capacity. We developed three qSAT assays for IgM, … Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
93
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 70 publications
(94 citation statements)
references
References 54 publications
1
93
0
Order By: Relevance
“…During the course of this work, many reports of serological diagnostic assays, including those based upon the Luminex format (15)(16)(17)(18)(19)(20)(21)(22)(23), have been presented. Rather than developing an additional diagnostic platform, we emphasize here the utility of the Luminex system as a research tool -for monitoring changes in antibody responses over time, detecting antibody responses in different sample matrices and for rapid adaptation and evaluation of new antigen formulations.…”
Section: Discussionmentioning
confidence: 99%
“…During the course of this work, many reports of serological diagnostic assays, including those based upon the Luminex format (15)(16)(17)(18)(19)(20)(21)(22)(23), have been presented. Rather than developing an additional diagnostic platform, we emphasize here the utility of the Luminex system as a research tool -for monitoring changes in antibody responses over time, detecting antibody responses in different sample matrices and for rapid adaptation and evaluation of new antigen formulations.…”
Section: Discussionmentioning
confidence: 99%
“…Up to date, there is no sufficiently effective antiviral drug to treat COVID-19. Therefore, the development of accurate and reliable diagnostic serological assays that can be readily applicable is crucial [1,2]. These assays should provide guidance to determine the seroprevalence of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the individual and community levels, identify immune presumptive protected persons who can serve as potential plasma donors, and for vaccine development [1].…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, the development of accurate and reliable diagnostic serological assays that can be readily applicable is crucial [1,2]. These assays should provide guidance to determine the seroprevalence of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the individual and community levels, identify immune presumptive protected persons who can serve as potential plasma donors, and for vaccine development [1]. In addition, serology assays are expected to play a critical role in testing the currently approved vaccines' efficiency by measuring the level of produced antibodies, determining their durability, and identifying thresholds of protection [3,4].…”
Section: Introductionmentioning
confidence: 99%
“…Whilst these results were obtained in the context of P. vivax-specific IgG responses in individuals from malaria-endemic areas, the large panel of proteins used and consistent results obtained for all proteins suggest these results can be applied to guide studies in other fields. Luminex 1 xMAP 1 technology has been used to measure antibody responses against other infectious pathogens, such as HIV and influenza [14,15], to a variety of vaccine antigens such as tetanus toxoid [16], and more recently to SARS-CoV-2 [17][18][19].…”
Section: Plos Onementioning
confidence: 99%